Acute hepatitis B infection does not usually require treatment because most adults clear the infection spontaneously. Early antiviral treatment may only be required in fewer than 1% of patients, whose infection takes a very aggressive course ("fulminant hepatitis") or who are immunocompromised. On the other hand, treatment of chronic infection may be necessary to reduce the risk of cirrhosis and liver cancer. Chronically infected individuals with persistently elevated serum alanine aminotransferase, a marker of liver damage, and HBV DNA levels are candidates for therapy.
Although none of the available drugs can clear the infection, they can stop the virus from replicating, and minimize liver damage such as cirrhosis and liver cancer. Currently, there are seven medications licensed for treatment of hepatitis B infection in the United States. These include antiviral drugs lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka) and entecavir (Baraclude) and the two immune system modulators interferon alpha-2a and pegylated interferon alfa-2a (Pegasys). The use of interferon, which requires injections daily or thrice weekly, has been supplanted by long-acting pegylated interferon, which is injected only once weekly. However, some individuals are much more likely to respond than others and this might be because of the genotype of the infecting virus or the patient's heredity. The treatment works by reducing the viral load (the amount of virus particles as measured in the blood), which Infants born to mothers known to carry hepatitis B can be treated with antibodies to the hepatitis B virus (hepatitis B immune globulin or HBIg). When given with the vaccine within twelve hours of birth, the risk of acquiring hepatitis B is reduced 95%. This treatment allows a mother to safely breastfeed her child.
On July 2005, researchers from A*Star and National University of Singapore identified an association between a DNA-binding protein belonging to the class of protein Heterogeneous nuclear Ribonucleoprotein K (hnRNP K) and HBV replication in patients. By controlling the level of hnRNP K may act as a possible treatment for HBV.
I am Marlene Schmdit , i live in Guwahati india, September 2015 I learned my HBsAg was reactive when I was required to undergo medical exam for an employment in abroad, and the doctor told me there is no permanent cure for the disease, I was worried and confused thought my life has come to an end, in December i came across a forum, (HEALTH MED LAB CLINIC) Who cured all kind of diseases including hepatitis b, I contacted them via email healthmedlab@gmail.com and made purchase of the hepatitis Vaccine, i received the Vaccine through Courier delivery within 3 days, when i received the Vaccine i applied it as prescribed and i was totally cured of hepatitis b within few's days of usages, i went back to my doctor and he confirmed i was free curable cured from the disease, am so happy now living a normal life again thanks to HEALTH MED LAB CLINIC. Viewers contact HEALTH MED LAB CLINIC via email: healthmedlab@gmail.com
ReplyDelete